Maximiliano Gelli
A5039672039- Hepatocellular Carcinoma Treatment and Prognosis
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Pancreatic and Hepatic Oncology Research
- Colorectal Cancer Treatments and Studies
- Intraperitoneal and Appendiceal Malignancies
- Liver Disease Diagnosis and Treatment
- Liver Disease and Transplantation
- Organ Transplantation Techniques and Outcomes
- Cancer Genomics and Diagnostics
- Gallbladder and Bile Duct Disorders
- Appendicitis Diagnosis and Management
- Gastric Cancer Management and Outcomes
- Neuroendocrine Tumor Research Advances
- Ovarian cancer diagnosis and treatment
- Cancer Cells and Metastasis
- Genetic factors in colorectal cancer
- Renal cell carcinoma treatment
- Cancer Treatment and Pharmacology
- Hepatitis C virus research
- Pancreatitis Pathology and Treatment
- Renal Transplantation Outcomes and Treatments
- Pediatric Hepatobiliary Diseases and Treatments
- Viral-associated cancers and disorders
- Cancer Immunotherapy and Biomarkers
- Intestinal and Peritoneal Adhesions
Institut Gustave Roussy
2016-2025
Université Paris-Saclay
2017-2025
Inserm
2020-2024
Hôpital Paul-Brousse
2013-2021
Université Paris-Sud
2020-2021
Assistance Publique – Hôpitaux de Paris
2013-2020
Improvement Service
2019
Université Paris Cité
2015-2019
Hôpital Beaujon
2019
Media Working Group
2018
Locoregional extension of intrahepatic cholangiocarcinoma (ICC) at the time diagnosis results in a low resectability rate and poor prognosis. The aim this retrospective study was to assess efficacy neoadjuvant chemotherapy for locally advanced ICC.All consecutive patients with ICC between 2000 2013 were included prospectively single-centre database analysed retrospectively. Patients considered as initially unresectable received primary chemotherapy, followed by surgery those secondary...
This multicenter study compares the outcomes of patients with cirrhosis undergoing liver transplantation (LT) or resection (LR) between January 2002 and July 2015 who had intrahepatic cholangiocarcinoma (iCCA) combined hepatocellular‐cholangiocarcinoma (cHCC‐CCA) found incidentally in native liver. A total 49 (65%) LT 26 (35%) LR histologically confirmed iCCA/cHCC‐CCA ≤5 cm were retrospectively analyzed. significantly lower tumor recurrence (18% versus 46%; P = 0.01), for which median...
Patient-derived organoids (PDOs) are promising tumor avatars that could enable ex vivo drug tests to personalize patients' treatments in the frame of functional precision oncology. However, clinical evidence remains scarce. This study aims evaluate whether PDOs can be implemented practice benefit patients with advanced refractory pancreatic ductal adenocarcinoma (PDAC).
3500 Background: Despite the increasing efficacy of chemotherapy (CT) and advances in surgical techniques for initially unresectable colorectal liver metastases (uCLM), secondary resection rate remains low. For definitively uCLM, CT standard care but transplantation (LT) has shown promising results. This first randomized trial aimed to assess combined LT uCLM. Methods: Patients with uCLM from resected BRAF non mutated cancer, having responded (≥ 3 months ≤ lines) absence extrahepatic...
Abstract Background Data on recurrence patterns following hepatectomy for colorectal liver metastases (CRLMs) and their impact long-term outcomes are limited in the setting of modern multimodal management. This study sought to characterize of, factors associated with, survival initial CRLMs. Methods A retrospective cohort patients undergoing CRLMs at 39 institutions (2006–2013) was conducted. Kaplan–Meier methods were used analyses. Overall landmark analysis 12 months after performed compare...
Abstract Background The peritoneal cancer index (PCI) is a comparative prognostic factor for colorectal metastasis (CRPM). ability of laparoscopy to determine the PCI in consideration cytoreductive surgery remains undetermined, and this study was designed compare it with laparotomy. Methods A prospective multicentre conducted patients no known CRPM, but at risk disease. Surgery began laparoscopic exploration followed by open PCI. Concordance between assessment evaluated diagnosis CRPM...
The aim of this study was to assess the outcomes patients operated on for peritoneal metastases from unusual cancer sites origin, meaning apart (PM) colorectal, gastric and epithelial ovarian carcinomas, pseudomyxoma peritonei mesothelioma.A questionnaire concerning treated with cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) PM arising origin sent all centres, which routinely performed HIPEC, through Peritoneal Surface Oncology Group International RENAPE...
Cell migration is essential to living organisms and deregulated in cancer. Single cell's ranges from traction-dependent mesenchymal motility contractility-driven propulsive amoeboid locomotion, but collective cell has only been described as a focal adhesion-dependent process. Here, we show that cancer clusters, patients lines, migrate without adhesions when confined into nonadhesive microfabricated channels. Clusters coordinate behave like giant super cells, mobilizing their actomyosin...
This study evaluated the efficacy of hyperthermic intraperitoneal chemotherapy (HIPEC) in colorectal cancer with peritoneal metastases (pmCRC) a large international data set patients.
Abstract Background The incidence of gastric poorly cohesive carcinoma (PCC) is increasing. prognosis for patients with peritoneal metastases remains poor and the role cytoreductive surgery (CRS) hyperthermic intraperitoneal chemotherapy (HIPEC) controversial. aim was to clarify impact PCC treated by CRS or without HIPEC. Methods All from cancer HIPEC, in 19 French centres, between 1989 2014, were identified institutional databases. Clinicopathological characteristics outcomes compared...
Abstract Background Patient Derived Organoids (PDOs) emerged as the best technology to develop ex vivo tumor avatars. Whether drug testing on PDOs identify efficient therapies will bring clinical utility by improving patient survival remains unclear. To test this hypothesis in frame of trials, PDO faces three main challenges be implemented routine practices: i) generating with a limited amount material; ii) wide panel anti-cancer drugs; and iii) obtaining results within time compatible...